GlobeNewsWire · EVX · October 23, 2026

Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

Get the app for more

Explore stock news, insights and company research.